FY2029 Earnings Forecast for VERA Issued By Wedbush

Vera Therapeutics, Inc. (NASDAQ:VERA) – Equities researchers at Wedbush issued their FY2029 EPS estimates for shares of Vera Therapeutics in a note issued to investors on Thursday, February 27th. Wedbush analyst L. Chico forecasts that the company will earn $2.16 per share for the year. Wedbush currently has a “Neutral” rating and a $38.00 target price on the stock. The consensus estimate for Vera Therapeutics’ current full-year earnings is ($2.89) per share. Wedbush also issued estimates for Vera Therapeutics’ FY2029 earnings at $2.16 EPS.

Vera Therapeutics (NASDAQ:VERA) last announced its quarterly earnings data on Wednesday, February 26th. The company reported ($0.72) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.83) by $0.11.

A number of other equities research analysts have also recently commented on the stock. The Goldman Sachs Group assumed coverage on shares of Vera Therapeutics in a report on Tuesday, January 28th. They set a “buy” rating and a $58.00 price target on the stock. Guggenheim lifted their target price on Vera Therapeutics from $59.00 to $61.00 and gave the stock a “buy” rating in a report on Thursday. Wells Fargo & Company started coverage on Vera Therapeutics in a report on Thursday, November 21st. They set an “overweight” rating and a $70.00 price target on the stock. Wolfe Research assumed coverage on Vera Therapeutics in a report on Tuesday, February 4th. They issued an “outperform” rating and a $49.00 price objective for the company. Finally, JPMorgan Chase & Co. boosted their target price on Vera Therapeutics from $72.00 to $75.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 5th. One analyst has rated the stock with a hold rating, six have issued a buy rating and three have given a strong buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $65.11.

Vera Therapeutics Stock Performance

Shares of Vera Therapeutics stock opened at $29.41 on Friday. The stock has a market cap of $1.86 billion, a price-to-earnings ratio of -11.27 and a beta of 1.11. The company has a debt-to-equity ratio of 0.17, a current ratio of 13.76 and a quick ratio of 13.76. Vera Therapeutics has a 1 year low of $25.99 and a 1 year high of $51.61. The firm’s 50-day moving average is $36.00 and its 200 day moving average is $40.35.

Insider Transactions at Vera Therapeutics

In related news, CEO Marshall Fordyce sold 17,500 shares of the business’s stock in a transaction that occurred on Wednesday, December 18th. The shares were sold at an average price of $43.07, for a total transaction of $753,725.00. Following the completion of the sale, the chief executive officer now directly owns 85,942 shares in the company, valued at approximately $3,701,521.94. The trade was a 16.92 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders have sold 52,500 shares of company stock worth $2,305,625 in the last quarter. Company insiders own 21.70% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of VERA. Huntington National Bank bought a new position in Vera Therapeutics in the 4th quarter worth $26,000. AlphaQuest LLC purchased a new stake in Vera Therapeutics in the fourth quarter worth about $34,000. GF Fund Management CO. LTD. bought a new position in shares of Vera Therapeutics in the fourth quarter worth about $56,000. Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Vera Therapeutics by 21.4% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,983 shares of the company’s stock valued at $86,000 after buying an additional 350 shares in the last quarter. Finally, KBC Group NV grew its stake in shares of Vera Therapeutics by 127.2% during the 4th quarter. KBC Group NV now owns 2,477 shares of the company’s stock valued at $105,000 after acquiring an additional 1,387 shares during the period. Hedge funds and other institutional investors own 99.21% of the company’s stock.

About Vera Therapeutics

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.